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Abstract: Prediction parameters of possible outcomes of canine leishmaniasis (CanL) therapy might
help with therapeutic decisions and animal health care. Here, we aimed to develop a diagnostic
method with predictive value by analyzing two groups of dogs with CanL, those that exhibited
a decrease in parasite load upon antiparasitic treatment (group: responders) and those that maintained
high parasite load despite the treatment (group: non-responders). The parameters analyzed were
parasitic load determined by q-PCR, hemogram, serum biochemistry and immune system-related
gene expression signature. A mathematical model was applied to the analysis of these parameters to
predict how efficient their response to therapy would be. Responder dogs restored hematological
and biochemical parameters to the reference values and exhibited a Th1 cell activation profile with
a linear tendency to reach mild clinical alteration stages. Differently, non-responders developed
a mixed Th1/Th2 response and exhibited markers of liver and kidney injury. Erythrocyte counts
and serum phosphorus were identified as predictive markers of therapeutic response at an early
period of assessment of CanL. The results presented in this study are highly encouraging and may
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represent a new paradigm for future assistance to clinicians to interfere precociously in the therapeutic
approach, with a more precise definition in the patient’s prognosis.
Keywords: mathematical model; treatment; hematological parameters; biochemical parameters;
Leishmania
1. Introduction
Canine leishmaniasis (CanL) is a severe disease caused by the protozoa Leishmania infantum [1–3].
As a zoonotic infection, L. infantum is a major health concern, since it also causes human visceral
leishmaniasis, a neglected tropical disease, in the Americas, Europe, North Africa, the Middle East and
China [4]. Dogs are susceptible to the development of high parasitic loads, playing a key role in the
transmission cycle of L. infantum via phlebotomine sand flies in endemic areas [5,6]. Higher parasite
loads in dogs are related to more severe clinical disease [7] and higher infectiousness to sand flies [5].
As full-blown disease is associated with active infection [8], efficacy of CanL treatment should be
primarily centered in its capability of reducing L. infantum load.
Treatment of CanL is a challenge for veterinary practitioners regarding anti-parasitical efficacy,
adverse effects and cost. Current leishmanicidal drugs, such as antimonials, miltefosine and allopurinol,
can clinically cure dogs or temporarily improve clinical signs, but no evidence of efficacy in terms of a
parasitological cure exists for any of them [8,9]. Consequently, clinical recurrences associated with high
parasite loads in a number of treated dogs are frequent at diverse time intervals post treatment [10].
In Brazil, where most of the South American cases of L. infantum infection occur, the use of antimonials
for canine treatment is prohibited [11].
The success of some antileishmanial protocols in reducing L. infantum load and blocking parasite
transmission to phlebotomine vectors have been evidenced by xenodiagnoses [12–14]. However,
failure of anti-Leishmania therapy depends on drug pharmacodynamic effects, parasite’s inherent
virulence or drug resistance development and host’s immune and nutritional status, or co-infections,
which contribute decisively to the recurrence [15,16]. Prognosis of response to treatment largely
depends on the severity of the visceral disease, as determined by the clinicopathological alterations,
particularly those related to renal function [17,18].
Because dogs respond differently to anti-parasite treatments and there are still no predictive tools
to discriminate dogs that respond to therapy from those that maintain high parasitic loads despite
treatment, we aimed at devoting the present study to this aspect. This study was a retrospective
longitudinal analysis of parasitological, biochemical and hematological parameters in a cohort of
dogs treated for CanL with second-line antileishmanial drugs, as reported in the literature [8,9,19–22].
The study’s objective was to identify biomarkers and to develop a prototype mathematical model with
predictive value to estimate the success of a leishmanicidal therapy as a tool for improved diagnosis
and treatment monitoring.
2. Materials and Methods
2.1. Ethics Approval
This work was approved by the Ethics Committee on Animal Use of the Federal University
of Bahia, Brazil (CEUA-UFBA, n. 19/2011), substantiated in the bioethical principles of animal
experimentation. All procedures were followed in accordance with the guidelines of the Brazilian
Council of Animal Experimentation (CONCEA—Conselho Nacional de Controle de Experimentação
Animal) and strictly followed the Brazilian law for “Procedures for the Scientific Use of Animals”
(11.794/2008). All manipulation in dogs, whether invasive or non-invasive, was performed or monitored
by veterinarians. The group of non-responder dogs was designed based on the parasitic load whose
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quantitative test was performed at the end of the study. Therefore, throughout the course of the
study, dogs that developed other diseases or acquired co-infections were removed to receive proper
additional treatment.
2.2. Animals and Sampling
A one-year longitudinal analysis of hematological and biochemical parameters was conducted in
26 dogs, naturally infected by L. infantum in the state of Bahia in Brazil, submitted to leishmanicidal
treatment. The inclusion criteria were confirmed infection with Leishmania spp. via parasitological
and/or molecular techniques, and consent of the guardians for the treatment with the multi-drug
antiparasitic regimen (metronidazole + ketoconazole + allopurinol). The coexistence of other diseases
or co-infections and terminal CanL were the exclusion criteria in the beginning and at any other
time of examination in the course of the follow-up. Dogs were evaluated at six different time points
during the year. The time 0 (T0) consisted of the moment in which the dogs arrived at the Zoonotic
Leishmaniasis Outpatient Clinic at the Teaching Hospital of Veterinary Medicine of the Federal
University of Bahia (ALZ-UFBA) for diagnosis and first clinical care. Dogs were evaluated monthly
during the first three months (T1, T2, T3), and then at the sixth (T6) and twelfth month (T12)
post-treatment. At each evaluation, blood was collected from the jugular or cephalic vein and stored in
EDTA tubes (BD Vacutainer; Becton, Dickinson) for hemogram and search for hematozoa. Blood was
also collected into EDTA-free tubes (BD Vacutainer; Becton, Dickinson) for the determination of
serological and biochemical parameters. Urine was collected by cystocentesis (in females) and urethral
catheterization (in males) for urinalysis and urinary protein-creatinine ratio (UPC). For the collection of
bone marrow and spleen samples by aspiration biopsy (performed at T0, T6 and T12), 20 mL syringes
and needles 40 × 12 mm and 40 × 16 mm were used respectively, inserted in an anatomic-topographic
region of the spleen [23] and sternum [24], with previous local antisepsis and mild sedation with
acepromazine (0.02 mg/kg).
2.3. Clinical Evaluation and Staging
Dogs were clinically evaluated for the presence or absence of CanL-compatible clinical signs and
definition of clinical staging, as determined by the LeishVet Group guidelines [8]. Weight loss, appetite
alterations, facies, mucosal staining, dermatopathies (ulcers, cutaneous vasculitis, onychogryphosis,
desquamation, alopecia, crusts, hyperkeratosis, depigmentation of snout, nodule), lymphadenopathy,
ophthalmopathy, presence or absence of fever, diarrhea, epistaxis and enlargement of the spleen by
palpation were assessed. Based on clinical and laboratory parameters, dogs were categorized in clinical
staging I (mild disease), II (moderate disease), III (severe disease) or IV (very severe to terminal disease).
2.4. Anti-Leishmania Chemotherapy
Antiparasitic treatment consisted in the administration of metronidazole (25 mg/kg/twice daily)
for 30 days associated to ketoconazole (10 mg/kg/once a day) for 40 days, followed by a maintenance
treatment with allopurinol (10 mg/kg/twice daily) during at least one year. Prednisolone was given
(beginning with 0.5 mg/kg/twice daily) for 30 days (including gradual withdrawal) [20,25,26] to
minimize systemic immune complex formation, thus indirectly to prevent kidney injury during the
four-week initial course of treatment with anti-leishmanial drugs. The multi-drug therapeutic regimen
for CanL used in the present study has been previously described [14].
2.5. Hematological and Biochemical Parameters
Hemograms, characterization of blood cell morphology and search for hematozoa infection
were performed as described [27]. The following biochemical parameters were measured: enzymes
(alanine aminotransferase (ALT), aspartate transaminase (AST), creatine kinase (CK) and its
isoenzyme creatine kinase MB (CK-MB), pseudocholinesterase and gamma-glutamyl transferase
(GGT) (Cormay, Łomianki, Poland)), protein (albumin and total protein (Cormay, Łomianki, Poland)),
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substrates (creatinine, urea) and electrolytes (calcium, phosphorus and magnesium (Spinreact,
Barcelona, Spain)). The urinary protein-creatinine (UPC) and serum calcium/phosphorus ratio were also
quantified. All variables were measured in the automatic (Prestige 24i, Tokyo Japan) and semi-automatic
(BioPlus-200, São Paulo Brazil) biochemical analyzer, as described [28].
2.6. Quantification of Total Globulin and Specific Anti-Leishmania Antibodies
For the quantification of total globulins, total protein values were subtracted from albumin
values. Specific anti-Leishmania IgG antibodies were quantified in the sera as previously described [29],
with minor modifications. Ninety-six-well plates (BioLegend, San Diego USA) were coated with
10 µg/mL of L. infantum soluble promastigote antigens. After washing with 3% PBS-low-fat-milk
and 0.05% PBS-Tween (PBS-T), 100 µL/well of canine serum diluted 1:50,000 in PBS-T was added
in duplicate and incubated at 30 min at 37 ◦C. The reaction was completed by adding the anti-dog
IgG-HRP diluted at 1:5000 (Bethyl Laboratories, Montgomery, USA) for 30 min at 37 ◦C, and further
incubation with 0.5 mg/mL of o-phenylenediamine dihydrochloride (OPD, Sigma, Darmstadt Germany)
for 10 min. The reaction was stopped using 50 µL/well of 3 M HCl. Plates were read at 492 nm (Synergy,
Biotek, Tokyo Japan).
2.7. Parasitic Load
DNA of the collected aspirated bone marrow and spleen at T0, T6 and T12 was extracted using the
commercial kit PureLink Genomic DNA® (Invitrogen, Carlsbad USA) following the manufacturer’s
recommendations. The quality and concentration of the DNA in each eluate were evaluated in the
L-QUANT spectrophotometer (Loccus, São Paulo Brazil). For the quantification of L. infantum DNA in
the spleen and bone marrow samples, qPCR assays were performed using the protocol described by
Rolão et al. [30], with some modifications. The primers 5′-GGTTAGCCGATGGTGGTCTT-3′ (forward),
5′-GCTATATCATATGTCCAAGCACTTACCT3′ (reverse) and the probe TaqMan® (Applied Biosystems
Foster City USA) (5′- ACCACCTAAGGTCAACCC-3′) were used. The final reaction volume (25 µL)
consisted of 4 µL of DNA, standardized at the concentration of 20 ng/µL, 12.5 mL of Mastermix
Universal® (Life Technology Corporation, Carlsbad USA), 5 µM of each primer and 10 µM of the probe
TaqMan. qPCR was run at 95 ◦C for 10 min, 40 cycles at 95◦ C for 15 s and 60 ◦C for 1 min. All samples
were analyzed in duplicate. Reactions were performed on the Applied Biosystems 7500 Real-Time
PCR System (Life Technology Corporation Carlsbad USA).
2.8. Quantitative PCR
Splenic mRNA expression of cytokines IFN-γ, IL-2, TNF-α, IL-17A, IL-22, IL-4, IL-5 and IL-10 was
determined using real time PCR. Spleen fragments were macerated for total RNA extraction using
Trizol reagent (Invitrogen, Carlsbad USA), as recommended by the manufacturer. RNA concentration
was determined by OD260 measurement using a L-quant 1.0 spectrophotometer (Loccus®, São Paulo,
Brazil). cDNA synthesis was performed using 1 µg of total RNA plus 10 µL of High-Capacity
cDNA Reverse Transcription master mix (Applied Biosystems, Foster City USA), according to the
manufacturer instructions. Real-Time quantitative PCR (qRT-PCR) reactions were run for each
sample on a Bio-Rad CFX96 Real-Time System C1000 Thermal Cycler (Bio-rad Berkeley USA). Primer
sequences were obtained from IDT (Lovaina, Belgium) and thoroughly tested. Specific oligonucleotides
are: IL2 (forward) CCCAAGAAGGCCACAGAATTTA, (reverse) TCCTTGGTGTCTGTCAAGTGAA;
IL4 (forward) CTAGCACTCACCAGCACCTT, (reverse) CACGAGTCGTTTCTCGCTGT; IL5 (forward)
GGCGATGGGAACCTGATGAT, (reverse) CGTGGGCAGTTTGGTTCTTC; IL10 (forward)
CAAGCCCTGTCGGAGATGAT, (reverse) AGAAATCGGTGACAGCGTCG; IFNG (forward)
TCAAATTCCTGTGAACGATCTGC, (reverse) TTATTTCGATGCTCTGCGGC; TNFA (forward)
CTCCAACTAATCAGCCCTCTTG, (reverse) GGGTTTGCTACAACATGAGCTACT; GAPDH (forward)
GCTGGTGCTGAGTATGTTGTGGAG, (reverse) CAGCAGAAGGAGCAGAGATGATGA. The RT
product was expanded using the NZYSpeedy qPCR Green Master Mix kit (NZYTech, Lisbon Portugal)
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and results were normalized to the expression of the housekeeping gene Gapdh. After amplification,
cycle threshold-values (Ct-values) were calculated for all samples and gene expression changes were
analyzed in the CFX Manager Software (Bio-Rad) and represented as arbitrary units (AU).
2.9. Statistical Analysis
The Kruskal–Wallis test followed by the Dunn test were used for data analysis between two groups.
A one-way analysis of variance (ANOVA) followed by a Bonferroni’s post-hoc test was employed
for multiple group comparisons. Exploratory logistic regression models were made in R using the
package Bias Reduction in Binomial-Response Generalized Linear Models [31,32]. The Chi-square test
was used for statistical analysis to evaluate the significant association between variables. Data are
reported as means ± standard deviation (SD). Statistically significant values are as follows: * p < 0.05,
** p < 0.01, *** p < 0.001.
3. Results
3.1. Responder Dogs Exhibit a Decrease in Splenic and Bone Marrow Parasite Loads and Improvement of
Clinical Staging
Leishmania infantum absolute parasite load evolution in spleen and bone marrow of a cohort
of dogs under leishmanicidal treatment for 12 months were distinct between two groups. Dogs that
presented a significant reduction in parasite loads from T0 to T12 were grouped as chemotherapy
Responders (GR, 46%, 12 dogs), while those that failed to have the parasite burden reduced were
grouped as Non-Responders (GNR, 54%, 14 dogs; Figure 1A, B). At T0, before treatment, there were
no parasitic loads’ differences between groups in both organs (Figure 1A, B), as well as in the clinical
staging (Figure 1C). At T6, GR exhibited a noticeable parasitic load reduction in comparison to that of
GNR. After one year of treatment (T12), GR’s parasitic loads were significantly lower than those at T0
(p < 0.001) in both tissues (Figure 1A, B), having decreased 97.3% and 98.5% in bone marrow and spleen,
respectively. In opposition, no significant difference was observed for GNR (Figure 1A, B). At T0,
both groups presented the same clinical stage—II, characterized by moderate disease. Accompanying
the parasite load data, at T12, GR exhibited on average a mild disease (stage I), while GNR remained
in stage II (Figure 1C).
Figure 1. Responder dogs exhibited decreased parasite loads and improved the clinical staging.
The canine cohort was separated into responder and non-responder dogs regarding the effect of
anti-Leishmania chemotherapy. The parasite burden was quantified by qPCR in the spleen (A) and bone
marrow (B) before and at 6- and 12-months post-treatment. The clinical stage of each dog was recorded
at the time of the diagnosis (T0) and upon 1 (T1), 2 (T2), 3 (T3), 6 (T6) and 12 (T12) months of treatment
(C). Data are shown as mean ± standard deviation (SD), Responder dogs (n = 12) Non responder dogs
(n = 14). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
3.2. Responder Dogs Display a Th1 Signature
We next addressed the immune response developed by GR and GNR. The median monocytes’
counts was similar and within the reference range in both groups (Figure 2A). The lymphocytes’ counts,
however, changed at T3 and T6 (Figure 2B), not only increasing from T2 to T3 within GR, but also
becoming consistently higher than those of GNR at T3 and T6. To further explore, we performed a
qPCR analysis on spleen samples at T0, T6 and T12. The GR exhibited a Th1 signature, with increased
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levels of IL2, IFNG and TNFA transcripts at T6 (Figure 2C), while no differences were found in IL17
nor IL22 (Supplementary Figure S1A). Moreover, a significant reduction on IL10 transcripts of GR
was accompanied by similar levels of Th2-associated IL4 and IL5 cytokines (Figure 2C), indicating an
effective Th1 response underlying the protective response. Remarkably, these effects on transcripts
could be verified in all individual dogs analyzed (Supplementary Figure S1B, C). Overall, our data
showed that increased levels of blood lymphocytes and a splenic Th1 response guide the response
to therapy.
Figure 2. Responder dogs display Th1 signature. The serum absolute numbers of monocytes (A) and
lymphocytes (B) was quantified from T0 until 12 months post treatment. mRNA was isolated from
spleen biopsies at T0, T6 and T12. Quantitative PCR was performed for IFNG, TNFA, IL2, IL4, IL5 and
IL10 (C). Data are shown as mean ± SD or in a box and whisker plot format, Responder dogs (n = 9)
Non responder dogs (n = 8) * p < 0.05; ** p < 0.01.
3.3. Non-Responder Dogs Failed to Restore the Hematological Parameters to Normal Reference Values
At T0, average GR dogs displayed median erythrocyte counts, hemoglobin and hematocrit
levels within the normal reference range, while in GNR dogs, those parameters were sub-optimal
(Figure 3A–C). Of note, at T0, 8 out of 14 (57.14%) of GNR had anemia; of these, 4 out of 8 (50%)
presented a reticulocyte counting below 60 × 103/mm3 (had non-regenerative anemia). Regarding the
GR dogs, 3 out of 12 (25%) were anemic, with 2 of these presenting a reticulocyte counting superior to
60 × 103/mm3 (had regenerative anemia). At T12, 9 out of 13 (69.2%) GNR dogs were anemic, compared
to none of the GR dogs; among those 9 dogs, only one presented a reticulocyte counting superior to
60 × 103/mm3. This is strongly suggestive that non-regenerative anemia indeed progressed in the
GNR group of dogs during the one year of follow up, despite treatment. Total globulin levels were
increased in both groups, but the GR displayed a significantly lower level (Figure 3D). Interestingly,
the difference in globulins was not equivalent to anti-Leishmania-specific IgG titters, which could not
discriminate GR from GNR (Figure 3E).
The cohort of dogs was monitored during one year through hematological and biochemical
analysis performed at one-, two-, three-, six- and twelve-months post-treatment (T1, T2, T3, T6 and T12)
(Figure 3A–D). Although a tendency for hematological improvement was observed in all parameters
until the third month of treatment, non-responder dogs declined in months 6 and 12 (Figure 3A–D).
In opposition, all responder dogs displayed erythrocyte numbers, hemoglobin and hematocrit within
the normal reference values upon 12 months of treatment, apart from total globulins, where 3 out of
11 dogs still presented values above the upper limit (Figure 3A–D). Moreover, the observed recovery
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of responder dogs was accompanied by a significant reduction in the anti-Leishmania-specific IgG
(Figure 3E).
Figure 3. Success of anti-Leishmania therapy is associated with a restoration of erythrocyte, hemoglobin,
hematocrit, as well as total and Leishmania-specific globulin values. Erythrocyte number (A) and
the values of hemoglobin (B), hematocrit (C), total globulins (D) and anti-Leishmania IgG (E) were
quantified in the serum at diagnosis (0) and upon 1, 2, 3, 6 and 12 months of anti-Leishmania treatment.
Data are shown as box and whisker plot format, Responder dogs (n = 12), Non responder dogs (n = 14).
* p < 0.05; ** p < 0.01.
Finally, given that our data was suggestive that erythrocyte number, hemoglobin and hematocrit
values can be predictive of the therapeutic response in a first moment of evaluation of sick dogs,
before treatment, we calculated the relative risk (RR) and the 95% confidence interval (CI) to determine
the likelihood of each of these parameters to be associated with the progression of CanL upon treatment.
A significant association between decreased hemoglobin (3.14 RR with 1.14–8.7 CI), hematocrit (3.75 RR
with 1.05–13.38 CI) and erythrocyte levels (1.82 RR with 0.88–3.73 CI) with the failure of CanL treatment
was observed, reinforcing their utility to the prediction of therapeutic response.
3.4. Serum Biochemistry Parameters Are Predictive of Visceral Organ Injury in Non-Responder Dogs
Serum levels of hepatocellular damage markers, alanine and aspartate transaminase
(Supplementary Figure S2A, B), and biliary tract disease marker γ-glutamiltransferase (Supplementary
Figure S2C), were within the reference range during follow-up in both groups. However, cholinesterase
and albumin, proteins synthesized in the liver, were significantly reduced in the GNR at T0, T6 and T12
(Figure 4A and Supplementary Figure S2D). In GNR, while urea and creatinine values were within the
reference range (Supplementary Figure S2E, F), the urinary protein/creatinine ratio (UPC), a predictor
of renal disease, was elevated (Figure 4B). These peculiar changes are indicative of early hepatic and
renal disease in the GNR. The values of hematological, serum biochemistry and parasitic load of the
initial and final times of the responder and non-responder dogs to the treatment are shown in Table 1.
Figure 4. Non-responder dogs develop sub-clinical hepatic and renal lesions. Serum values of
cholinesterase (A) and urine protein/creatinine ratio (B) were quantified at T0, T1, T2, T3, T6 and T12.
Data are shown as mean ± SD or in a box and whisker plot format, Responder dogs (n = 12),
Non responder dogs (n = 14). * p < 0.05; ** p < 0.01.
Microorganisms 2020, 8, 745 8 of 15
Table 1. Values of hematological, serum biochemistry, oxidative stress parameters and parasitic load of the initial and final times of the responder and non-responder
dogs to the treatment
Parameters Responders (R) p-Value (T0 vs. T12) Non Responders (NR) p-Value (T0 vs. T12) Normality Value p-Value (T0 R vs. T0 NR)
Hematology T0 T12 T0 T12
Erythrocyte (x106/µL) 6.68 6.73 0.497 5.01 4.97 0.940 5.5–8.5 0.033
Hemoglobin (g/dL) 15.03 14.75 0.771 10.21 10.54 0.885 12–18 0.0002
Hematocrit (%) 41.82 45.12 0.689 31.2 32.78 0.641 37–55 0.0023
Leucocytes (x103/µL) 9.6 13 0.120 8.9 8,8 0.935 6–17 0.345
Lymphocytes (x103/mm3) 1.69 1.92 0.373 1.92 1.41 0.181 1–4.8 0.406
Monocytes (/mm3) 493 424 0.606 457 429 0.972 150–1350 0.776
Reticulocytes (x103/mm3) 90 34.6 0.144 51.6 46.1 0.678 <60 0.303
Serum biochemistry
Total proteins (g/dL) 8.6 7.7 0.102 9 8.6 0.254 5.4–7.1 0.426
Albumin (g/dL) 2.79 3.04 0.167 2.21 2.54 0.260 2.6–3.3 0.017
Globulins (g/dL) 5.7 4.3 0.032 6.7 6.2 0.186 2.7–4.4 0.045
Albumin/Globulin (A/G) ratio 0,5 0,8 0.0682 0,4 0,5 0.242 0.5–1.7 0.081
Calcium (mg/dL) 11.73 10.50 0.330 10.87 10.39 0.218 9–11.3 0.064
GGT (U/L) 5.78 4.54 0.329 4.73 6.11 0.218 1–10 0.736
Creatinine (mg/dL) 1.26 1.0 0.082 1.0 1.2 0.330 0.5–1.4 0.920
Urea (mg/dL) 43.8 37.6 0.579 36.2 22.55 0.060 21–60 0.591
Cholesterol (mg/dL) 22.9 33.5 <0.0001 20.71 28.8 0.001 31–71 0.112
Magnesium (mg/dL) 1.62 2.22 0.264 1.66 1.86 0.017 1.8–2.4 0.104
HDL (mg/dL) 57.6 145.2 <0.0001 45.5 112.9 <0.0001 33–120 0.062
Triglycerides (mg/dL) 75.72 73.42 0.853 72.7 100 0.029 20–112 0.333
ALT (UI/L) 51.2 66.9 0.830 42.4 66.8 0.117 21–102 0.214
FA (UI/L) 74.97 86.82 0.587 101 124.7 0.933 20–156 0.255
AST (UI/L) 23.96 32.82 0.087 40.93 32.82 0.615 23–66 0.368
Glucose (mg/dL) 93.7 90 0.472 90.8 87.5 0.617 65–118 0.497
Iron (µg/dL) 280.07 85.29 0.094 360.4 142.2 0.075 30–180 0.149
Phosphorous (mg/dL) 3.24 2.84 0.401 4.61 3.074 0.011 2.5–6.0 0.0085
Potassium (mmol/L) 13.40 13.38 0.980 14.95 14.42 0.229 12.3–15.7 ** 0.0023
CK (U/L) 47.08 152.39 <0.0001 37.35 87.79 0.106 100–200 ** 0.504
CK-MB (U/L) 145.71 24.84 0.310 82.07 38.07 0.121 31–38.8 0.432
Cholinesterase (U/L) 4022.2 4200.5 0.737 3,198 2,807 0.911 1210–3020 0.057
UPC 0.48 0.31 0.113 0.44 0.85 0.342 0.5 # 0.833
Serologic
ELISA (OD)—Anti-Leishmania IgG 0.42 0.13 0.032 1.27 0.81 0.155 0.17 ** 0.324
Parasite Load
Spleen (Parasite Burden (log10)) 3.225 1.398 <0.0001 3.761 4.252 0.969 0.382
Bone marrow (Parasite Burden (log10)) 2.580 0.408 <0.0001 2.879 2.579 0.431 0.748
Hematology and serum biochemistry normality value (NV) Source: Kaneko et al. [33]. NV—# UPC < 0.5 healthy animals; 0.5–1.0 bordering; >1.0 glomerular proteinuria. Source:
Solano-Gallego et al. [5]. T0: time 0 (before treatment); T12: time 12 (12 months of treatment). ** NV based on the negative control values of the study. All significant values are shown
in bold.
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3.5. Development of a Mathematical Model with Predictive Value for the Success of CanL Chemotherapy
Apart from erythrocytes, hemoglobin and hematocrit (Figure 3A–C), phosphorous, and to a
lesser extent, potassium and albumin also significantly discriminated GR from GNR at T0 (Figure 5A).
High Spearman correlation coefficients were found between erythrocytes, hematocrit and hemoglobin
(Figure 5B). Logistic regression models with the lowest Akaike information criterion (AIC) and higher
accuracy using a leave-one-out cross-validation were selected for phosphorus plus one of the three
highly correlated variables erythrocytes, hematocrit or hemoglobin (Figure 5C). The highest accuracy
was obtained considering phosphorus and erythrocytes. For this case, the log(odds) of a successful
treatment, using the full dataset, can be given by:
log(odds) = 14.067 − 5.289 × [Phosphorus] + 1.170 × Number of erythrocytes (1)
Figure 5. Development of a mathematical model with predictive value for the success of
CanL chemotherapy including the measurement of the erythrocyte and phosphorus parameters.
(A) The serum values of phosphorous, potassium and albumin were quantified at T0). (B) The
Spearman linear correlation coefficient is shown for serum albumin, hematocrit, erythrocytes,
hemoglobin, phosphorous and potassium values. (C) Scatterplots between phosphorous and hematocrit
or erythrocytes or hemoglobin serum values. Data are shown as mean ± SD or in a box and whisker
plot format. Responder dogs (n = 12), Non responder dogs (n = 14). *p < 0.05; **p < 0.01.
The probability is obtained by applying the logistic function: (exp(x)/(1 + exp(x)), where x is the
log(odds). Remarkably, this formula allowed 100% discrimination between GR and GNR, demonstrating
the high predictive power of our mathematical model.
4. Discussion
Until recently, most studies of prognostic factors for treatment success or failure in leishmaniasis
were restricted to humans [33–37], and the infected dog has been seen only as a protozoan reservoir.
This is an innovative longitudinal study of prognostic factors in L. infantum naturally infected dogs
under treatment that resulted in a clear distinction of two profiles of CanL dogs that responded
differently to the same antiparasitic therapy, based on their tissue parasite load reduction. Dogs with
reduced parasite numbers are less likely to develop clinical signs and are less infectious to vectors [5].
Studies indicate that the successful resolution of Leishmania infections depend on a response
characterized by IFN-γ, IL-2 and TNF-α predominance, which increase phagocytic efficiency and
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lymphocyte cytotoxicity, triggering a protective immune response [38,39]. Accordingly, we observed
that responder dogs exhibited a consistent Th1 signature that accompanied parasitism reduction upon
treatment, in opposition to the non-responder group.
In the present study, the standard parameters for clinical staging of CanL [8] and follow-up of
the dogs, such as albumin/globulin ratio, non-regenerative anemia or renal functions, were assessed
individually from the beginning to the end of the study. However, only at the end of the one-year
study did the treatment outcome allow the determination of which dogs could be classified as
responders or non-responders. The evident dichotomy between GR and GNR dogs allowed for
identifying two laboratory parameters predictive of therapeutic success: erythrocyte counts and serum
phosphorus dosage. Anemia is commonly observed in human and canine leishmaniasis and can
originate from reduced production and/or increased destruction of erythrocytes [27,40,41]. During
chronic inflammatory diseases, anemia results from low iron circulating levels, while inflammatory
cytokines such TFN-α, IL-1 and IFN-γ inhibit erythropoiesis, and erythrocyte membrane damage
by oxidizing agents shortens the lifespan of erythrocytes [42]. In chronic infections such as CanL,
these damaged erythrocytes are retained and destroyed in the spleen, which becomes enlarged as
a clinical sign of the disease. This is accompanied by a dysregulation of iron transporting proteins
leading to the accumulation of storage iron [43,44]. This explains the normocytic normochromic type of
anemia most dogs had in the beginning of the present study, which also demonstrates the improper iron
supplementation during the treatment, as already described in the literature [45–47]. In chronic renal
disease, which is common in CanL, anemia also results from decreased erythropoietin production in the
kidney [8,48]. Kidneys are the main route for phosphorus excretion and hyperphosphatemia promotes
progressive renal lesions [49], as described in dogs with late-stage CanL [50]. Serum globulin and acute
phase proteins levels, proteinuria and UPC ratio are considered biomarkers for the clinical monitoring
of dogs during leishmanicidal treatment and post-treatment [3,17,18,51,52]. However, very few studies
have approached the identification of factors, to be used as reliable prognosis predictors, based on
the outcome (death or cure) upon therapy [53]. In the present study, moderate-stage CanL dogs
exhibited overall serum phosphorus—a marker of renal failure—within the reference range, but the
logistic regression models clearly indicated that phosphorus’ in addition to erythrocyte’s changes were
sensitive enough to predict chemotherapy success or failure.
Phosphorus interplays with calcium via modulation of several hormones and their serum
concentration is approximately inversely related [50]. Overall, non-responder dogs of our study
displayed lower magnesium, higher phosphorus and lower Ca/P ratio compared to responder
dogs, with renal consequences demonstrated by elevated UPC ratio. Renal impairment-related ion
imbalances underlie several clinical manifestations; for instance, magnesium is an enzymatic cofactor
that participates in diverse metabolic reactions [40,54], including those related to erythropoiesis [55,56].
Cholinesterase and albumin serum levels normalized in responder dogs after six months of
therapy, unlike in non-responders. As the liver is a site of L. infantum activity [57], this discrete
interference with hepatic synthetic function could explain our findings in non-responder dogs. Here,
serum urea and creatinine were within the reference values in both group of dogs. This corroborates
literature data showing that azotemia is an uncommon finding, despite elevated frequencies of renal
pathologies in CanL [58]. Creatinine is a by-product of CK, whose levels are reduced in dogs with
LCan [59]; therefore, we suggest that this bias of azotemia diagnosis in advanced CanL results
from sub-concentration of creatinine and might lead to kidney disease underdiagnoses. It has been
stressed in the literature that the active infection by L. infantum and CanL progression relates with
immune complex-mediated disease [60], which plays an important role in the pathophysiology of
diverse clinical manifestations, including immune-mediated hemolytic anemia, glomerular lesions
and renal failure [38,61]. In this sense, prednisolone was chosen as an anti-inflammatory drug in
the present study during the short-term in all dogs to minimize the formation and circulation of
soluble immune complexes and reduce inflammation through an inhibitory effect on complement
activation [62,63]. Glucocorticoid therapy benefits in the treatment of CanL have been described
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previously [20,25,26]. It is worth mentioning that several studies have shown that the short- or
long-term oral glucocorticoid administration in dogs do not induce significant changes in the several
hematological and biochemical parameters [64–67]. The four-week course of prednisolone did not seem
to have interfered with the biomarkers evaluated herein, as evaluations at T1 did not behave differently
than those seen at subsequent follow-up points, as demonstrated in Figures 2–4. Upon corticotherapy
at anti-inflammatory doses, a discrete elevation in liver enzymes is expected in dogs, as previously
described [66,68].
Altogether, we developed a mathematical formula using erythrocytes and phosphorus as markers
for a prognosis of antiparasitic therapy success in CanL at the time of first diagnosis. Nevertheless,
the study displays the reduced cohort studied, and the use of second line anti-parasite drugs, given the
constraints for therapeutic approaches to CanL in Brazil, as major limitations. Because this was a
long-term clinical study, it resulted in a small number of dogs that were followed up until the last
evaluation. Nevertheless, the gathered data was so consistent that it allowed the creation of the
formula, which can be an initial guide for further studies with larger sample sizes and different
methods of cross-validation and in cohorts treated with first-line drugs. Taken together, these results
are highly encouraging and may represent a new paradigm for clinical assistance, allowing a precocious
therapeutic interference based on an improved diagnosis.
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